8-K: Kairos Pharma to Host KOL Event on ENV105 Prostate Cancer Data

Kairos Pharma announced a virtual KOL event to discuss interim efficacy results from its Phase 2 trial of ENV105 for advanced prostate cancer.

Summary

• Kairos Pharma, Ltd. (NYSE American: KAPA) will host a virtual Key Opinion Leader (KOL) event on Thursday, September 18, 2025, at 5 p.m. ET / 2 p.m. PT.
• The event will discuss diverse perspectives on the company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients.
• This predetermined efficacy analysis occurs four months after the start of combination therapy of ENV105 and apalutamide in the last safety lead-in patient.
• The panel of experts will include Dr. Neil Bhowmick (President and Chief Scientific Officer at Kairos Pharma), Dr. Umang Swami (Huntsman Cancer Institute), Dr. Richard Lee (Massachusetts General Hospital, Harvard Medical School), and Dr. Edwin Posadas (Samuel Oschin Comprehensive Cancer Institute).

Sentiment

Score: 7

Explanation: The announcement of a KOL event to discuss efficacy results, following positive safety data, suggests confidence in the drug's potential. While no efficacy data is presented yet, the proactive engagement with experts is a positive signal for future developments in a high-need area.

Positives

• Hosting a premier KOL event suggests confidence in the upcoming interim efficacy data for ENV105.
• Interim safety analysis, announced in July 2025, demonstrated that ENV105 was well tolerated when combined with standard of care hormone therapy, apalutamide, in the first 10 enrolled patients.
• No dose-limiting toxicities or unexpected adverse events have been reported to date in the trial.
• Treatment-related side effects were manageable with standard supportive care, and notably, no Grade 3 or 4 toxicities were observed.
• ENV105 is a first-in-class CD105 antagonist, targeting a key driver of resistance to various cancer treatments, addressing a significant unmet medical need in castration-resistant prostate cancer.

Negatives

• No specific efficacy data from the Phase 2 trial is provided in this filing; the event is to discuss the results, not to announce them directly.
• The filing includes standard cautionary statements regarding forward-looking information, highlighting inherent challenges and uncertainties in product research and development.

Risks

• Challenges and uncertainties are inherent in product research and development, which could impact the success of ENV105.
• There is uncertainty regarding the future commercial success of ENV105, even if clinical trials are successful.
• Actual results could vary materially from expectations and projections if underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize.
• Kairos Pharma is not obligated to publicly update or revise any forward-looking statement, except as required by U.S. federal securities laws.

Future Outlook

Kairos Pharma aims to provide a safe and effective alternative for patients with castration-resistant prostate cancer using ENV105. The company is focused on overcoming drug resistance and immune suppression in cancer, with ENV105 also in a Phase 1 trial for lung cancer. Management hopes to lay out the primary benefits of ENV105 and clearly demonstrate the clinical need it fills.

Management Comments

• "The safety results of the trial are an important catalyst as we prepare for the announcement of our interim efficacy results in treating prostate cancer patients." Dr. John Yu, CEO of Kairos Pharma.
• "This predetermined efficacy analysis occurs four months after start of combination therapy of ENV105 and apalutamide in the last safety lead-in patient." Dr. John Yu, CEO of Kairos Pharma.
• "We hope to lay out the primary benefits of our compound, and to clearly demonstrate the clinical need filled by ENV105." Dr. John Yu, CEO of Kairos Pharma.
• "This distinguished panel of experts will provide participants with a renewed understanding of the importance of these data and the role ENV105 can have in targeting cancer drug resistance." Dr. John Yu, CEO of Kairos Pharma.

Industry Context

The development of resistance to current hormone therapies in prostate cancer is a growing unmet need, particularly with an aging population. Castration-resistant prostate cancer (CRPC) represents a significant challenge, as treatment options become limited once hormone therapies fail. Kairos Pharma's ENV105, a CD105 antagonist, aims to address this by reversing drug resistance and restoring the effectiveness of standard therapies, positioning it in a high-need area within oncology.

Stakeholder Impact

• Shareholders: Potential for increased investor interest and share price volatility based on the KOL event's outcome regarding ENV105's efficacy.
• Patients (Advanced Prostate Cancer): Potential for a new, effective treatment option (ENV105) addressing drug resistance, if efficacy results are positive.
• Medical Community: Opportunity to gain deeper insights into ENV105's potential role in treating advanced prostate cancer from leading experts.

Next Steps

• Host a virtual KOL event on September 18, 2025, to discuss interim efficacy results of ENV105 in advanced prostate cancer.
• Continue the Phase 2 clinical trial for ENV105 in castrate-resistant prostate cancer.
• Continue the Phase 1 trial for ENV105 in lung cancer.
• Prepare for potential future regulatory approval following the conclusion of trials.

Key Dates

Recommendation

While the interim safety data for ENV105 is positive and the company is proactively engaging with Key Opinion Leaders to discuss upcoming efficacy results, no actual efficacy data has been released in this filing. The KOL event on September 18, 2025, will be a critical catalyst. Investors should hold to await the outcome of this event and the subsequent release of detailed efficacy data before making a more definitive investment decision.

Keywords

Kairos Pharma, KAPA, ENV105, Prostate Cancer, Advanced Prostate Cancer, Castration-Resistant Prostate Cancer, CRPC, CD105 antagonist, Phase 2 trial, Clinical Trial, Oncology, Biopharmaceutical, Cancer Therapeutics, KOL Event, Efficacy Results, Drug Resistance, Apalutamide